Approval · Notice of Compliance 220 · 2002
LIPITOR: Notice of Compliance 220
Issued February 19, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 220
- Date
- February 19, 2002
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: raises hdl-cholesterol and therefore lowers the ldl-c/hdl-c and total-c/hdl-c ratios in patients with primary hypercholesterolemia and combined (mixed) hyperlipidemia (fredrickson type iia and iib dyslipidemia)
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LIPITOR | Not yet assigned | — |
Medicinal ingredients
- ATORVASTATIN CALCIUM 10 MG per TAB
- ATORVASTATIN CALCIUM 20 MG per TAB
- ATORVASTATIN CALCIUM 40 MG per TAB
- ATORVASTATIN CALCIUM 80 MG per TAB